51736-77-7

Basic information

• Product Name: 6''-O-carbamoyltobramycin
• Synonyms: 6''-O-carbamoyltobramycin;6-O-(3-Amino-6-carbamoyl-3-deoxy-α-D-glucopyranosyl)-4-O-(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)-2-deoxy-D-streptamine;TobraMycin CarbaMate;nebramycin 5'
• CAS NO: 51736-77-7
• Molecular Formula: C19H38N6O10
• Molecular Weight: 510.541
• Mol File: 51736-77-7.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 840.8°C at 760 mmHg
• Flash Point: 462.3°C
• Appearance: /
• Density: 1.54g/cm³
• Vapor Pressure: 7.55E-33mmHg at 25°C
• Refractive Index: 1.646
• PKA: 13.00±0.70(Predicted)
• CAS DataBase Reference: 6''-O-carbamoyltobramycin(CAS DataBase Reference)
• NIST Chemistry Reference: 6''-O-carbamoyltobramycin(51736-77-7)
• EPA Substance Registry System: 6''-O-carbamoyltobramycin(51736-77-7)

Safety Data

• Hazardous Substances Data: 51736-77-7(Hazardous Substances Data)

Usage

Description

6''-O-carbamoyltobramycin is a carbamoylkanamycin derivative of tobramycin, an aminoglycoside antibiotic. It features a single carbamoyl substituent located at the 6'' position on the 3-aminoglucose ring, which is a key structural modification that can potentially alter its properties and interactions with biological systems.

Uses

Used in Pharmaceutical Industry:
6''-O-carbamoyltobramycin is used as an antibiotic agent for the treatment of various bacterial infections. The carbamoyl substitution at the 6'' position may enhance its efficacy, potentially leading to improved treatment outcomes and reduced resistance development in bacteria.
Used in Research and Development:
In the field of pharmaceutical research and development, 6''-O-carbamoyltobramycin serves as a valuable compound for studying the structure-activity relationships of aminoglycoside antibiotics. This knowledge can be applied to design and develop novel antibiotics with improved properties, such as increased potency, reduced side effects, and enhanced resistance to bacterial resistance mechanisms.
Used in Drug Delivery Systems:
Similar to gallotannin, 6''-O-carbamoyltobramycin may also benefit from novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. These systems could include encapsulation in nanoparticles, liposomes, or other carriers, which can protect the antibiotic from degradation, improve its solubility, and facilitate targeted delivery to the site of infection.
Used in Combination Therapies:
6''-O-carbamoyltobramycin may be used in combination with other antibiotics or antimicrobial agents to create synergistic effects, enhancing the overall efficacy of the treatment and potentially reducing the likelihood of resistance development. This approach can be particularly useful in treating multi-drug resistant bacterial infections.

InChI:InChI=1/C19H38N6O10/c20-3-9-8(26)2-7(23)17(32-9)34-15-5(21)1-6(22)16(14(15)29)35-18-13(28)11(24)12(27)10(33-18)4-31-19(25)30/h5-18,26-29H,1-4,20-24H2,(H2,25,30)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1